CART-19 Cells For R/R B-ALL — CCFRRBA  

Relapsed/Refractory B-cell ALL Clinical Trial

Official title: CART-19 Cells For Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Status Recruiting

Clinical Trial Summary

There are limited treatment options for relapse/refractory B-cell acute lymphoblastic leukemia(ALL). However,CART-19 cells has emerged as a powerful targeted immunotherapy for highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients with relapse/refractory B-cell ALL.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Relapsed/Refractory B-cell ALL

• NCT number: NCT03391739
• Study type: Interventional
• Source: Fujian Medical University
• Contact: Jianda Hu, Prof.M.D.Ph.D
• Phone: 86-13959169016
• Email: drjiandahu@163.com
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: January 2016
• Completion date: December 2019